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Abstract Objective: To evaluate
whether classification of patients as
having low, moderate, or high stress
based on clinical parameters is asso-
ciated with plasma levels of stress
hormone Design and setting:
Prospective, blinded, observational
study in an 18-bed medical ICU.
Patients: Eighty-eight consecutive
patients Interventions: Patients were
classified as low (n=28), moderate
(n=33) or high stress (n=27) on days
0 and 3 of ICU stay, based on 1 point
for each abnormal parameter: body
temperature, heart rate, systemic ar-
terial pressure, respiratory rate,
physical agitation, presence of infec-
tion and catecholamine administra-
tion. The stress categories were: high:
4 points or more, moderate 2–3
points, low 1 point. Plasma growth
hormone (GH), insulin-like growth
factor 1 (IGF-1), insulin, glucagon,
cortisol were measured on days 0 and
3. Measurements and results: Plasma
cortisol and glucagon were signifi-
cantly higher and IGF-1 lower in high
vs. low stress patients on days 0 and
3. High stress patients were more
likely to have high cortisol levels
(odds ratio 5.8, confidence interval
1.8–18.9), high glucagon (8.7, 2.1–
36.1), and low IGF-1 levels (5.9, 1.8–
19.0) than low stress patients on day
0. Moderate stress patients were also
more likely to have high cortisol and
glucagon levels than low stress pa-
tients. Insulin and GH did not differ
significantly. Results were similar for
day 3. Conclusions: Moderate and
severe stress was significantly asso-
ciated with high catabolic (cortisol,
glucagon) and low anabolic (IGF-1)
hormone levels. The hormonal stress
level in ICU patients can be estimated
from simple clinical parameters dur-
ing routine clinical evaluation.
Keywords Growth hormone ·
Insulin-like growth factor 1 ·
Cortisol · Glucagon · Insulin ·
Stress level
Introduction
Many intensive care unit (ICU) patients present with
hypermetabolism and catabolic stress state which leads to
major endogenous protein breakdown and is associated
with respiratory and nonrespiratory muscle wasting [1].
Muscle mass wasting is accompanied by physical weak-
ness with prolonged physical rehabilitation and/or an in-
creased likelihood of difficult weaning from the ventila-
tor. The latter increases the risk of nosocomial infections
such as pneumonia which in turn is responsible for further
catabolism.
Stress is defined as the effects produced when a
stressor (such as trauma, injury, and infection) acts upon a
structure, system or organism. When stress occurs in
quantities that the system cannot handle, it produces
pathological changes, including muscle catabolism [2].
Thus stress level is the main modulator of the catabolic
process, which drives the progression of malnutrition and
leads to impaired functional status. To minimize muscle
wasting therapy should aim at identifying the level of
hormonal stress. Since nutritional support is one of the
therapeutic strategies to limit catabolism, timely inter-
vention that is proportional to the stress level is desirable.
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Patients with a low stress level probably require standard
nutritional support only, and support can be delayed 3–
5 days, as recommended by the ESICM [3], but it should
not be delayed in moderately and highly stressed patients
with increased metabolic demands and compromised
nutritional status. Early intervention in malnourished, el-
derly, and highly stressed patients is essential to prevent
protein-energy malnutrition [4, 5] and major catabolism.
The early detection of the stress level of ICU patients
could prove valuable by allowing a timely intervention to
promote anabolism and reduce catabolism.
Thus identifying hormonal stress is important. How-
ever, the tools necessary for the clinical evaluation of the
stress level of ICU patients have so far not been defined.
Traditionally, cortisol and glucagon have been used as
indicators of hormonal stress. However, these measure-
ments are complex, expensive, and not immediately
available. For this reason we classified ICU patients into
three stress categories (low, moderate, high) by using
easily defined clinical parameters. We compared the
clinical parameters to plasma hormone levels at admis-
sion and after 3 days in the ICU. The aim of this stress
classification was to evaluate the level of catabolism
without using labor- and cost-intensive investigations to
determine whether nutritional support should be started
early or later in moderately ill patients.
The aim of this prospective, blinded study was to
evaluate whether the classification of patients as having
low, moderate, or high stress levels based on easily ob-
tainable clinical parameters is associated with the levels
of catabolic (cortisol, glucagon) and anabolic hormones
(growth hormone, GH); insulin-like growth factor 1, IGF-
1; insulin). This is a pilot study that requires further
validation.
Methods
Patients
The study was approved by the Ethics Committee of the
Internal Medicine Department. All patients admitted to
the medical ICU were considered for inclusion unless
they presented with any of the following exclusion cri-
teria: preexisting renal failure (serum creatinine 
300 mmol/l), insulin-treated type 2 diabetes, pituitary,
adrenal or thyroid insufficiency, and neuromuscular dis-
ease, including paralyzed patients. Patients who could not
be included within 8 h after admission were also ex-
cluded. During a 1-month period 100 consecutive patients
of 141 were included; 41 were excluded because they
either did not meet inclusion criteria or they were not
assessed within 8 h of admission to the ICU. Of the re-
maining 100 patients, 12 dropped out because of death
(n=3), transfer to the surgical ICU or non-ICU ward (n=6)
or missing values (n=3). The study thus included 88
evaluable (aged 17–84 years). The main clinical charac-
teristics and diagnoses are presented in Table 1. The
stress-defined groups did not differ significantly in sex,
age, body mass index, or standard blood chemistry test
results. Of the patients in the high-stress group 74% were
hospitalized because of septic shock, cardiac arrest, or
acute respiratory distress syndrome. Moderate-stress pa-
tients were admitted to the ICU predominantly for res-
piratory insufficiency (73%). Low-stress patients were
hospitalized mostly for myocardial infarction and angina
(75%). A bed scale was used to determine body weight
with a precision of €50 g and body height was measured
with a precision of €0.5 cm. Patients received nutritional
support (oral, enteral, parenteral) according to our stan-
dard ICU protocol. Nutritional intake was progressively
increased according to predicted requirements and toler-
ance.
Clinical evaluation
Patients were included in the study within 8 h of ICU
admission, when the initial assessment was made. A
second evaluation was performed 72 h later. Clinical di-
agnosis on admission was recorded and clinical scoring of
the hormonal stress level of the patients was performed by
one of two authors (P.J. and J.C.C.), both senior certified
ICU physicians. Both clinicians and laboratory techni-
Table 1 Physical characteristics and diagnosis of study groups
evaluated on day 0 (APACHE Acute Physiology and Chronic
Health Evaluation, ARDS acute respiratory distress syndrome,
COPD chronic obstructive pulmonary disease, SAPS Simplified
Acute Physiology Score)
High
(n=27)
Moderate
(n=33)
Low
(n=28)
Sex: M/F 17/10 20/13 21/7
Age (years) 61.3€16.7 59.5€18.1 57.4€18.1
Length of stay (days)** 12.0€8.4 6.0€4.7 2.9€2.5
Geneva Clinical
Assessment*
4.5€0.6 2.7€0.5 0.5€0.5
APACHE II Score* 12.8€4.3 13.7€5.8 6.7€3.5
SAPS* 10.9€4.1 10.5€4.3 5.2€2.9
Body mass index 24.4€6.2 25.7€7.3 27.1€6.2
Diagnosis
Septic shock 9 – –
ARDS 6 – –
Cardiac arrest 5 2 –
Cardiogenic
pulmonary edema
– 3 –
Myocardial infarction – – 5
Unstable angina – – 10
Myocarditis – – 6
Respiratory pathologies 1 7 3
COPD 1 15 1
Asthma 3 2 –
Liver failure 2 3 –
Other – 1 3
*p<0.05 (analysis of variance), **p<0.50 (Kruskal-Wallis)
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cians were blinded to each others’ results until the end of
the study. Patients were classified as low, moderate, or
high stress. Classification of stress categories was based
on the following clinical criteria: (a) body temperature
36 or below or 38C or above; (b) heart rate 100/min or
higher; (c) mean systemic arterial pressure 60 or lower or
120 mmHg or higher; (d) respiratory rate 20/min or less;
(e) presence of infection, defined as a clear clinical source
and/or positive body fluids cultures; (f) physical agitation,
defined as a score higher than 5 on the Sedation-Agitation
Scale [6]; and (g) administration of exogenous cate-
cholamines other than low-dose dopamine
(2 g kg1 min1). Each of these items was assigned one
point if present, none if absent. Hence the minimum score
was 0, and the maximum 7.
These stress categories were based on the rationale of a
known association of the various parameters with both
severity of critical illness and increased metabolic de-
mand. Changes in body temperature, heart rate, arterial
pressure and respiratory rate are physiological parameters
used to determine the Acute Physiology and Chronic
Health Evaluation (APACHE) II score [7, 8] which have
been validated as markers of the severity of critical illness.
Likewise, infection [9], physical agitation [10], and ad-
ministration of exogenous cathecholamines [11] have all
been shown to increase metabolic activity in ICU patients.
At our hospital none of the patients are intubated with
etomidate, which is known to have an effect on the adrenal
function in patients with septic shock. On the other hand,
the levels of stress hormones decrease with sedation.
On the basis of the assigned points, patients were
categorized into three groups: high stress, those with 4
points or more; moderate stress, 2 or 3 points; low stress,
1 point. APACHE II score was also calculated for all the
patients [7]. In addition, all treatments (type, doses, and
duration) were recorded.
Catabolic and anabolic hormones
Abnormal plasma levels (high cortisol and glucagon, GH,
and insulin; low IGF-1) were used as reference method.
Normal values were: insulin 5–18 mU/l; glucagon 42–
111 ng/l; IGF-1, age-dependent; GH less than 10 g/l;
cortisol 200–700 nmol/l.
Plasma samples drawn from the indwelling radial ar-
tery catheter were prepared between 8 and 10 a.m. on
days 0 and 3 and frozen at 30C for subsequent deter-
minations of insulin (Imulite 2000 Insulin, Diagnostic
Products), coefficient of variation (CV) intra-assay
(8.3%) and interassays (8.6%); glucagon (RIA Linco
Research), CV intra-assay (5.4%) and interassays (7.9%);
IGF-1 (Nichols Institute Diagnostics), CV intra-assay
(2.4%) and interassays (5.2%); GH (Imulite 2000 hGH,
Diagnostic Products), CV intra-assays (4.6%) and in-
terassay (5.7%); and cortisol (Imulite 2000 Cortisol), CV
intra-assay (5.3%) and interassays (7.2%). Laboratory
results for routine blood chemistry (e.g., glucose, sodium)
were noted on a daily basis.
Statistical analysis
Results are expressed as mean €standard deviation for
normally distributed parameters. The differences between
stress groups analyzed by analysis of variance using
Statview 5.0. Multiple comparisons were evaluated by
Bonferroni’s method. Nonnormally distributed parameters
were expressed as median and range, and patient groups
were compared using the Kruskall-Wallis test for overall
analysis and Mann-Whitney nonparametric test for un-
paired samples for intergroup analysis. Pearson’s correla-
tion coefficient values were determined between clinical
stress category and hormone levels. Logistic regressions
were used to estimate odds ratios (OR) for various stress
categories. OR with 95% confidence intervals (CI) de-
scribe the magnitude of effects for each level of the study
variable compared with the reference category. Statistical
significance was set at p0.05 for all tests.
Results
Patients
Table 2 shows that four patients classified as high stress
on day 0 were classified as moderate stress on day 3 and
four as low stress at day 3. One moderate stress patient
was classified as high stress on day 3, and 15 moderate
stress patients became low stress on day 3. None of the
low stress patients at admission changed stress category
on day 3. Serum glucose and osmolarity were signifi-
cantly higher and serum protein was significantly lower in
high-stress than in low-stress patients on days 0 and 3
(Table 3). Serum potassium, blood urea nitrogen, and
creatinine did not differ significantly between patient
groups.
Table 2 Evolution of clinical assessment of stress in 88 ICU pa-
tients on days 0 and 3 after admission using seven clinical pa-
rameters
Stress category day 0 n Stress category day 3* n
High 27 High 19
Moderate 4
Low 4
Moderate 33 High 1
Moderate 17
Low 15
Low 28 High 0
Moderate 0
Low 28
*p<0.001 vs. day 0 (c2=3:76.4, 4 d.f.)
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Plasma hormone concentrations
Insulin levels did not differ significantly between stress
categories on days 0 or 3 (Table 4). Glucagon, cortisol,
and GH were higher and IGF-1 lower in high-stress than
in low-stress patients (p<0.01; Table 4). Levels of these
hormones were correlated with the clinical stress category
(p<0.05; Table 5). Stepwise multiple regressions includ-
ing age, cortisol, glucagon, IGF-1, GH, and insulin
showed that cortisol and IGF-1 were significant predictors
of the clinical stress category (p<0.001) and explained
27% of the variability. The prevalence of high glucagon
and cortisol and low IGF-1 was significantly greater in
high-stress than in low-stress patients. High-stress pa-
tients were more likely to have high glucagon (p<0.01)
and cortisol (p<0.05) and low IGF-1 (p<0.01) levels than
low stress patients (Table 6). Insulin and GH were not
associated with high stress level.
Discussion
The results of this study show that moderate and severe
stress is significantly associated with high catabolic
(cortisol, glucagon) and low anabolic (IGF-1) hormone
levels. We found a significant association between these
hormone levels and seven routine clinical parameters
(e.g., heart rate, fever, presence of infection), which
suggests that the levels of hormonal stress in medical ICU
patients can be estimated from simple clinical parameters
during routine clinical evaluation.
Patient characteristics and stress category classification
The patient population represented a wide range of ages
and included a representative sample of usual conditions
found in medical ICU patients. The attending physician
classified each patient included in the study protocol as
having low, moderate, or high stress at the time of ICU
admission and reclassified the patient after 3 days. The
significant association between simple clinical parameters
and catabolic (glucagon, cortisol) and anabolic hormone
levels (IGF-1) suggests that the hormonal stress state of
ICU patients can be determined by these simple clinical
parameters. Rapid clinical assessment of stress state
would be desirable in view of the poor clinical outcome in
patients who have high hormonal stress levels and are
malnourished at the same time [12]. Early detection of
increased risk would permit timely clinical intervention in
patients who are at high stress level or malnourished at
the time of ICU admission.
Table 3 Laboratory parameters by patient stress categories on days
0 and 3
Day 0 Severe Moderate Low
n=27 n=33 n=28
Glucose (mmol/l) 10.7€4.1 8.2€3.6* 6.9€2.3*
Sodium (mmol/l) 138.0€4.8 138.5€5.4 137.5€4.1
Potassium (mmol/l) 3.8€0.5 4.1€0.6 3.9€0.3
Protein (g/l) 62.9€10.0 64.4€6.3 67.6€5.9
Blood urea nitrogen
(mmol/l)
9.9€5.7 10.8€6.1 8.3€8.4
Creatinine (mmol/l) 116.4€49.1 112.2€50.4 92.9€25.5
Osmolarity
(mmol/kg)
294.2€14.0 293.7€11.5 287.8€8.0
Day 3 n=20 n=21 n=47
Glucose (mmol/l) 10.2€3.8 9.0€3.3* 6.8€2.2*,**
Sodium (mmol/l) 141.9€5.4 138.9€4.8 138.6€4.7*
Potassium (mmol/l) 4.1€0.3 4.2€0.5 3.9€0.3
Protein (g/l) 60.9€6.4 61.9€9.3 66.0€6.3*
Blood urea nitrogen
(mmol/l)
10.4€6.6 16.1€30.7 8.2€5.6
Creatinine (mmol/l) 104.4€46.7 97.4€66.4 110.2€75.8
Osmolarity
(mmol/kg)
301.8€17.2 295.8€11.9 290.9€14.6*
*p0.05 vs. moderate- or low-stress (analysis of vari-
ance),**p0.05 vs. moderate- and low-stress (post-hoc Bonfer-
roni’s test after one-factor analysis of variance)
Table 4 Plasma hormone levels measured on day 0 and 3 after admission to the ICU
Stress category Kruskal-
Wallis
p (Mann-Whitney)
High Moderate Low High vs.
moderate
Moderate
vs. low
High
vs. low
Day 0
Insulin (mU/l) 27.3 (4–585) 36.8 (8–178) 26.1 (4–189) 0.520 0.377 0.297 0.960
Glucagon (ng/l) 116 (36–801) 105 (33–2216) 64 (35–181) <0.001 0.513 <0.001 <0.001
Cortisol (nmol/l) 854 (231–1784) 806 (222–1968) 499 (174–1285) 0.001 0.427 0.003 0.001
IGF-1 (g/l) 34.9 (13–141) 53.9 (11–217) 78.9 (22–147) <0.001 0.019 0.105 <0.001
GH (g/l) 1.2 (0.2–36.5) 0.6 (0.0–12.3) 0.4 (0.2–7.8) 0.025 0.099 0.142 0.011
Day 3
Insulin (mU/l) 53 (9–289) 39 (8–193) 36 (7–245) 0.585 0.419 0.801 0.331
Glucagon (ng/l) 209 (45–1223) 119 (51–2394) 82 (32–940) <0.001 0.054 0.020 <0.001
Cortisol (nmol/l) 786 (329–1932) 708 (321–1956) 565 (71–1217) 0.020 0.230 0.144 0.008
IGF-1 (g/l) 39 (13–163) 51 (13–115) 72 (11–179) 0.005 0.179 0.139 0.001
GH (g/l) 2.8 (0.2–24.8) 1.4 (0.2–9.5) 0.5 (0.2–6.8) <0.001 0.315 0.003 <0.001
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The aim of this stress classification was not to predict
mortality, as with APACHE II or III scores, but to eval-
uate the relationship between stress and plasma hormonal
stress. The stress classification allows the evaluation of
the level of hormonal stress and thus catabolism and helps
to identify patients needing early nutritional support
without using labor- and cost-intensive investigations.
Consequently the APACHE II or III scores and the stress
classification do not have the same aim, are not intended
to be used interchangeably, and cannot be compared.
Relevance of plasma hormone measurements for hor-
monal stress assessment
Our goal was primarily to assess the degree of catabolism
in ICU patients by a clinical stress category which was
based on simple clinical parameters. The level of hor-
monal stress was assessed objectively by measuring
plasma levels of stress hormones, as previously reported
by others [13, 14, 15]. In hypermetabolic conditions
glucocorticosteroids play a major role in the loss of body
protein in acute catabolic disease by increasing proteol-
ysis and amino acid oxidation and by decreasing the ef-
ficacy of insulin to suppress proteolysis [16, 17].
Hypermetabolism and hypercatabolism are also me-
diated by proinflammatory cytokines, which have been
shown to cause muscle protein breakdown. On the other
hand, GH, IGF-1, and insulin levels have been shown to
be correlated to decreased proteolysis and amino acid
oxidation and to an increase in whole body protein syn-
thesis [16, 17]. Therefore five of the most potent plasma
hormonal factors which regulate protein metabolism (GH,
IGF-1, insulin, cortisol, and glucagon) known to vary in
response to hormonal stress were measured and compared
in relation to clinical parameters. IGF-1, glucagon, and
cortisol plasma levels were found to be better determi-
nants of hormonal stress than GH, and insulin was not at
all correlated with the three stress levels (Table 4). Plasma
cortisol levels increase with severity of stress [18] and has
been shown to be the best hormonal predictor of the de-
gree of lean body mass catabolism [19]. Cortisol is a
major determinant in the hormonal stress, and glucocor-
ticoid administration can influence plasma cortisol values.
Six patients received 200–300 mg/day hydrocortisone
(four high, one moderate, one low stress); seven received
100–200 mg/day (two high, four moderate, one low
stress); and six received less than 100 mg/day (one high,
four moderate, one low stress). We therefore performed a
post-hoc analysis to exclude patients who received glu-
Table 5 Statistical significance of simple correlations between
hormone levels and stress category measured on days 0 and 3 after
admission to the ICU. Normal laboratory values: insulin 5–18 mU/
l; glucagon 42–111 ng/l; insulin-like growth factor 1 (IGF-1);
growth hormone (GH) <10 g/l; cortisol 200–700 nmol/l
Day 0 Day 3
r p r p
Insulin 0.078 0.472 0.110 0.284
Glucagon 0.228 0.033 0.261 0.014
IGF-1 0.395 <0.001 0.438 <0.001
GH 0.290 0.006 0.336 0.001
Cortisol 0.383 <0.001 0.365 <0.001
Table 6 Odds ratio (95% CI) for abnormal, vs. normal, plasma
hormone concentrations, adjusted for age, for patients with mod-
erate or high vs. low stress category. Logistic regressions, adjusted
for age; normal laboratory values: glucagon 42–111 ng/l; insulin-
like growth factor-1 (IGF-1) age-dependent; cortisol 200–
700 nmol/l
Stress Day 0 Day 3
Low
value
Normal
value
High
value
OR (95% CI)
adjusted for
age
p Low
value
Normal
value
High
value
OR (95% CI)
adjusted for
age
p
Cortisol
Low – 18 (64.3%) 10 (35.7%) 1 – 30 (63.8%) 17 (36.2%) 1
Moderate – 12 (36.4%) 21 (63.6%) 3.4 (1.2–9.9) 0.026 – 10 (47.6%) 11 (52.4%) 2.1 (0.7–6.2) 0.172
High – 7 (25.9%) 20 (74.1%) 5.8 (1.8–18.9) 0.004 – 7 (35.0%) 13 (65.0%) 3.3 (1.1–10.0) 0.033
Glucagon
Low – 25 (89.3%) 3 (10.7%) 1 – 37 (78.7%) 10 (21.3%) 1
Moderate – 18 (54.5%) 15 (45.5%) 6.9 (1.7–27.5) 0.006 – 9 (42.9%) 12 (57.1%) 4.5 (1.4–13.8) 0.010
High – 13 (48.1%) 14 (51.9%) 8.7 (2.1–36.1) 0.003 – 3 (15.05%) 17 (85.0%) 21.8 (5.2–91.2) <0.001
IGF-1
Low 9
(32.1%)
19 (67.9%) – 1 18
(38.3%)
29 (61.7%) – 1
Moderate 16
(48.5%)
17 (51.5%) – 1.9 (0.7–5.6) 0.217 13
(61.9%)
8 (38.1%) – 3.6 (1.2–11.2) 0.025
High 20
(74.1%)
7 (25.9%) – 5.9 (1.8–19.0) 0.003 15
(75.0%)
5 (25.0%) – 5.5 (1.6–19.3) 0.006
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Acknowledgements We are indebted to R.C. Gaillard, E. Temler,
F. Ray, and M.C. Burnier for preparing and measuring some of the
biological samples.
1675
10. Terao Y, Miura K, Saito M, Sekino M,
Fukusaki M, Sumikawa K (2003)
Quantitative analysis of the relationship
between sedation and resting energy
expenditure in postoperative patients.
Crit Care Med 31:830–833
11. Schaffartzik W, Sanft C, Schaefer JH,
Spies C (2000) Different dosages of
dobutamine in septic shock patients:
determining oxygen consumption with
a metabolic monitor integrated in a
ventilator. Intensive Care Med
26:1740–1746
12. Griffiths RD (2003) Nutrition support in
critically ill septic patients. Curr Opin
Clin Nutr Metab Care 6:203–210
13. Roth-Isigkeit A, Brechmann J, Dibbelt
L, Sievers HH, Raasch W, Schmucker P
(1998) Persistent endocrine stress re-
sponse in patients undergoing cardiac
surgery. J Endocrinol Invest 21:12–19
14. Wray CJ, Mammen JM, Hasselgren PO
(2002) Catabolic response to stress and
potential benefits of nutrition support.
Nutrition 18:971–977
15. Nguyen NT, Goldman CD, Ho HS,
Gosselin RC, Singh A, Wolfe BM
(2002) Systemic stress response after
laparoscopic and open gastric bypass. J
Am Coll Surg 194:557–566–
16. Gore DC, Wolf SE, Sanford AP,
Herndon DN, Wolfe RR (2004) Ex-
tremity hyperinsulinemia stimulates
muscle protein synthesis in severely
injured patients. Am J Physiol En-
docrinol Metab 286:E529–E534
17. Carroll PV, Jackson NC, Russell-Jones
DL, Treacher DF, Sonksen PH,
Umpleby AM (2004) Combined growth
hormone/insulin-like growth factor I in
addition to glutamine-supplemented
TPN results in net protein anabolism in
critical illness. Am J Physiol Endocrinol
Metab 286:E151–E157
18. Span LF, Hermus AR, Bartelink AK,
Hoitsma AJ, Gimbrere JS, Smals AG,
Kloppenborg PW (1992) Adrenocorti-
cal function: an indicator of severity of
disease and survival in chronic critically
ill patients. Intensive Care Med 18:93–
96
19. Arnold J, Campbell I, Samuels I, Devlin
J, Green C, Hipkin L, MacDonald I,
Scrimgour C, Smith K, Rennie M
(1993) Increased whole body protein
breakdown predominates over in-
creased whole body protein synthesis in
multiple organ failure. Clin Sci (Lond)
84:655–661
20. Hamrahian AH, Oseni TS, Arafah BM
(2004) Measurements of serum free
cortisol in critically ill patients. N Engl
J Med 350:1629–1638
21. Houston-Bolze MS, Downing MT,
Sayed AM, Williford JH (1996) Gender
differences in the responses of serum
insulin-like growth factor and trans-
thyretin (prealbumin) to trauma. Crit
Care Med 24:1982–1987
22. Pichard C, Kyle U, Chevrolet JC, Jolliet
P, Slosman D, Mensi N, Temler E, Ri-
cou B (1996) Lack of effects of re-
combinant growth hormone on muscle
function in patients requiring prolonged
mechanical ventilation: a prospective
randomized controlled study. Crit Care
Med 24:403–413
23. Houston-Bolze MS, Downing MT,
Sayed AM, Williford JH (1996) Serum
insulin-like growth factor binding pro-
tein-3 responds differently to trauma in
men and women. Crit Care Med
24:1988–1992
24. Van den Berghe G, Baxter RC, Week-
ers F, Wouters P, Bowers CY, Veldhuis
JD (2000) A paradoxical gender disso-
ciation within the growth hormone/in-
sulin-like growth factor I axis during
protracted critical illness. J Clin En-
docrinol Metab 85:183–192
